Technology | Mammography | December 11, 2017

Siemens Healthineers Introduces Mammomat Revelation Mammography System for Improved Biopsy Workflow

3D HD Breast Biopsy uses company’s 50-degree wide-angle HD breast tomosynthesis to obtain more targeted, accurate biopsies at a lower dose; system also offers automated breast density measurement and titanium contrast-enhanced mammography exams

Siemens Healthineers Introduces Mammomat Revelation Mammography System for Improved Biopsy Workflow

December 11, 2017 — Siemens Healthineers unveiled the new Mammomat Revelation premium mammography platform at the 2017 Radiological Society of North America (RSNA) Annual Meeting, Nov. 26-Dec. 1 in Chicago. Mammomat Revelation enables healthcare providers to expand precision medicine, improve clinical outcomes and increase patient satisfaction, according to the company. The system’s HD Breast Biopsy solution enables one-click targeting of suspicious areas with a +/- 1mm accuracy. The new integrated specimen imaging tool facilitates immediate control of the biopsy directly at the mammography system. Clinical workflow is improved by eliminating the need for a second imaging system and by reducing patient compression time. Mammomat Revelation also provides automated breast density measurements at the point of care. Additionally, it expands existing diagnostic options and provides patient access to functional breast imaging with contrast-enhanced mammography.

With its 50-degree 3-D HD Breast Tomosynthesis, Siemens Healthineers said the system offers the widest scan angle available. This scan angle is the basis for what it calls the industry’s highest depth resolution, which provides extremely high-quality 3-D images to increase diagnostic confidence and enable earlier detection of even subtle lesions. With Mammomat Revelation, the clinician also can perform biopsies based on 3-D HD Breast Tomosynthesis. The HD Breast Biopsy solution enables one-click targeting of suspicious areas with a +/- 1mm accuracy.

Upon acquisition, the tissue sample must be X-rayed to confirm a successful biopsy. In clinical practice today, samples are usually imaged on a second system or on a dedicated specimen scanner, usually in a different room. During this time, the patient remains under compression. Mammomat Revelation can substantially reduce discomfort and anxiety with the InSpect integrated specimen imaging tool. Biopsy samples can be imaged and visualized at the technologist workstation within 20 seconds without radiation exposure to the patient. The system improves the biopsy workflow, shortens patient compression time and improves the patient experience.

In addition, Mammomat Revelation is the industry’s first mammography platform to provide automated breast density measurements at the point of examination, according to Siemens. Currently, radiologists must estimate breast density visually during the image reading process, which typically occurs after the patient has left the facility. Patients with high breast density at higher risk of developing breast cancer often require additional workup to rule out breast cancer. Additional imaging procedures require patient callbacks, which can lead to uncertainty and concern. The information provided by Mammomat Revelation not only enables immediate, personalized risk stratification, but it also allows the facility to provide supplemental imaging while the patient is at the facility. Patients receive results faster, minimizing patient uncertainty and stress.

In some cases, purely morphological information from a mammogram or tomosynthesis scan may be insufficient for a precise diagnosis. For example, distinguishing scar tissue from new lesions in a post-surgical examination can be difficult. In addition to purely morphological information, clinicians may require functional information that can be obtained through contrast-enhanced imaging, which is usually performed using breast magnetic resonance imaging (MRI). Mammomat Revelation enables functional imaging directly on the mammography system. Since mammography systems are more widely available than MRI scanners, patient access to more specific breast imaging tools can be improved. And since contrast-enhanced mammography is still not widely utilized, the modular arrangement of the new system enables its expansion to include this and other functionality on an as-needed basis.

Finally, discomfort and pain in addition to related anxiety are key reasons why patients avoid mammography exams. With Mammomat Revelation’s Personalized Soft Compression, the breast compression process is softened and the compression force is automatically and individually adjusted. Coupled with ergonomic SoftComp Paddles, Personalized Soft Compression enables better breast positioning, more consistent image quality, and reduced patient discomfort.

Mammomat Revelation and Insight BD are U.S. Food and Drug Administration (FDA) 510(k)-pending and are not commercially available in the United States.

For more information: www.usa.healthcare.siemens.com

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis
News | Mammography | July 10, 2019
Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-...
Therapixel Appoints Matthieu Leclerc-Chalvet as CEO
News | Artificial Intelligence | July 03, 2019
Artificial intelligence (AI) breast cancer screening specialist Therapixel announced the appointment of Matthieu...
GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

Feature | Breast Imaging | July 03, 2019 | By Greg Freiherr
Productivity and its enabler — efficiency — guided the display of products at the April...
Countless possibilities can impact the future of global healthcare and AI is the first step toward breakthrough that will change the landscape of personalized medicine
Feature | Women's Health | July 03, 2019 | By Samir Parikh
Contrary to what many people believe,...

Image courtesy of GE Healthcare

Feature | Radiology Business | July 03, 2019 | By Jeffrey Hoffmeister, M.D.
Burnout in the medical profession is not uncommon, particularly as clinicians have become more overwhelmed by growing
iCAD ProFound AI

Image courtesy of iCAD

News | Breast Imaging | June 25, 2019
Use of...